$USD1
Fading QuicklySnapshot Window: 2026-07-06 00:30 UTC · ← Back to Crypto Overview
Tracked Posts
1
Total Impressions
14
Total Likes
0
Retweets & Quotes
0
Comments
0
Social Momentum Summary
Total Engagement - Comments: 0, Retweets: 0, Likes: 0, Impressions: 14
Verbatim Community Citations & Social Evidence 1 source posts analyzed
中信证券研报认为,2026年下半年建议重点配置中国创新药,聚焦三类公司:一是创新药收入占比持续提升、商业化和盈利兑现能力较强的龙头Pharma/Biopharma;二是核心管线具备全球BIC/FIC潜力、已进入全球注册或后期临床阶段、未来数据和BD催化密集的创新平台;三是产品机制差异化明确、具备成长弹性和后续催化剂的成长型biotech。